Legacy Biotechnologies commences production of Reme-Flu

Nuvilex, Inc. (OTC Bulletin Board: NVLX), announces today that Legacy Biotechnologies, Inc., its joint venture partner in Reme-Flu™, has commenced production of Reme-Flu™ and expects it to be ready for consumer purchase within the next 30 days. Reme-Flu™ is Legacy Biotechnologies’ unique 2-part homeopathic flu remedy designed to help treat symptoms of the flu. Initially, Reme-Flu™ will be offered on the top-rated website, www.nutralegacy.com.

Nutralegacy.com, a site dedicated to education regarding a multitude of health related topics, receives an average of 190,000 unique visits every month. To mark the introduction of Reme-Flu™, Legacy Biotechnologies will be offering special incentives in order to make this important homeopathic flu remedy available to as many people as possible. It is vital to let consumers know that with Reme-Flu™, there is now a safe and effective way to treat symptoms of the flu – especially as seasonal weather patterns begin to change.

In addition, as Reme-Flu™ nears completion, Legacy Biotechnologies is actively pursuing an agreement with a major marketing company to work directly with both the sales and marketing of Reme-Flu™ in the retail sector. Legacy anticipates that a formal marketing agreement will be reached within the next week.

Martin Schmieg, President and CEO of Nuvilex, Inc., has stated that he is very pleased to see the production of Reme-Flu™ begin and feels that this remedy will be a great asset to help people of all ages overcome symptoms of the flu. The combination of a strong internet presence coupled with proven marketing methods will create a strong synergy in helping to quickly build sales and brand awareness of Reme-Flu™.